Natural products produced by microorganisms are a promising source of new drugs. Researchers at the Helmholtz Centre for Infection Research (HZI) and its Saarbrücken-based site, the Helmholtz Institute for...
From October 2026 to July 2027, Prof. Irah King, from McGill University in Montreal, Canada, will conduct research at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a site of the Helmholtz...
New active ingredients for drugs to treat infections, cancer, or other serious diseases are often based on substances originally discovered in microorganisms, plants, or other living organisms. Producing or improving...
Bacteriophages are viruses that exclusively infect bacteria and are therefore considered a promising treatment for antibiotic-resistant infections. The annual World Phage Day on October 22 also highlights this...
The World Health Organization (WHO) recently published a new position paper on COVID-19 vaccines. Dr. Henning Jacobsen, a researcher in the department “Viral Immunology” at the Helmholtz Centre for Infection Research...
Pulmonary fibrosis is currently incurable and leads to increasing shortness of breath. An international research consortium involving the Helmholtz Centre for Infection Research (HZI) and coordinated by Hannover Medical...
Treatment with broad-spectrum antibiotics often leads to side effects, as it affects not only the pathogens but also the “good” bacteria in the gut. A research team from Hannover Medical School (MHH), Saarland...
Through the Helmholtz Global Fellow Program, the Helmholtz Association supports outstanding international researchers whose projects bring fresh scientific momentum to Helmholtz centers. One of these fellows is Dr...
Why do the gut microbiomes of people from industrialized and non-industrialized regions differ? A study by the Helmholtz Centre for Infection Research (HZI) in collaboration with the European Molecular Biology...
